MA54741A - Composés thiényl-aniline destinés au traitement d'affections de la peau - Google Patents
Composés thiényl-aniline destinés au traitement d'affections de la peauInfo
- Publication number
- MA54741A MA54741A MA054741A MA54741A MA54741A MA 54741 A MA54741 A MA 54741A MA 054741 A MA054741 A MA 054741A MA 54741 A MA54741 A MA 54741A MA 54741 A MA54741 A MA 54741A
- Authority
- MA
- Morocco
- Prior art keywords
- thienyl
- treatment
- skin conditions
- aniline compounds
- aniline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862769832P | 2018-11-20 | 2018-11-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA54741A true MA54741A (fr) | 2021-11-24 |
Family
ID=70773567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA054741A MA54741A (fr) | 2018-11-20 | 2019-11-20 | Composés thiényl-aniline destinés au traitement d'affections de la peau |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12466818B2 (fr) |
| EP (1) | EP3911313A4 (fr) |
| JP (1) | JP7546297B2 (fr) |
| CN (2) | CN117551073A (fr) |
| AU (1) | AU2019384645B2 (fr) |
| CA (1) | CA3120352A1 (fr) |
| MA (1) | MA54741A (fr) |
| WO (1) | WO2020106305A1 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3120337A1 (fr) | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Composes naphthyridinone-aniline destines au traitement d'affections de la peau |
| CA3120351A1 (fr) * | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Composes aryl-aniline et heteroaryl-aniline pour le traitement de cancers de la peau |
| MA55141A (fr) | 2018-11-20 | 2021-09-29 | Nflection Therapeutics Inc | Composés cyanoaryl-aniline pour le traitement d'affections de la peau |
| JP7546297B2 (ja) | 2018-11-20 | 2024-09-06 | エヌフレクション セラピューティクス インコーポレイテッド | 皮膚障害の処置のためのチエニル－アニリン化合物 |
| US11010862B1 (en) * | 2019-11-14 | 2021-05-18 | Advanced Micro Devices, Inc. | Reduced bandwidth tessellation factors |
| EP4436570A4 (fr) | 2021-11-23 | 2025-10-22 | Nflection Therapeutics Inc | Formulations de composés de pyrrolopyridine-aniline |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4271164A (en) | 1979-04-16 | 1981-06-02 | Warner-Lambert Company | 6-Substituted-arylpyrido[2,3-d]pyrimidin-7-amines and derivatives |
| GB9420168D0 (en) | 1994-10-06 | 1994-11-23 | Boots Co Plc | Therapeutic agents |
| NZ501277A (en) | 1997-07-01 | 2002-12-20 | Warner Lambert Co | -2(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors |
| IL132840A (en) | 1997-07-01 | 2004-12-15 | Warner Lambert Co | Derivatives 4 - bromo or 4 - benzohydroxamic acid iodine amino iodine and pharmaceutical preparations containing them for use as MEK inhibitors |
| JP2910748B2 (ja) | 1997-11-12 | 1999-06-23 | 日本電気株式会社 | 異質同軸部材の端面の球状加工装置及びその方法 |
| AU2482700A (en) | 1999-01-13 | 2000-08-01 | Warner-Lambert Company | 1-heterocycle substituted diarylamines |
| DE60330227D1 (de) | 2002-03-13 | 2010-01-07 | Array Biopharma Inc | N3-alkylierte benzimidazol-derivate als mek-hemmer |
| WO2003090688A2 (fr) | 2002-04-24 | 2003-11-06 | Van Andel Research Institute | Accentuation de la melanogenese epidermique chez l'homme |
| RU2324695C2 (ru) | 2002-08-06 | 2008-05-20 | Ф.Хоффманн-Ля Рош Аг | 6-АЛКОКСИПИРИДОПИРИМИДИНЫ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ АКТИВНОСТЬЮ ИНГИБИТОРОВ КИНАЗЫ МАР р38 |
| CN1905873A (zh) | 2003-11-19 | 2007-01-31 | 阵列生物制药公司 | Mek的杂环抑制剂及其使用方法 |
| CA2565965A1 (fr) * | 2004-05-06 | 2006-07-27 | Plexxikon, Inc. | Inhibiteurs de pde4b |
| JP4163738B2 (ja) | 2004-06-11 | 2008-10-08 | 日本たばこ産業株式会社 | 癌の治療用の５−アミノ−２，４，７−トリオキソ−３，４，７，８−テトラヒドロ−２Ｈ−ピリド’２，３−ｄ！ピリミジン誘導体及び関連化合物 |
| US7674907B2 (en) | 2004-07-23 | 2010-03-09 | Amgen Inc. | Furanopyridine derivatives and methods of use |
| MX2007004781A (es) | 2004-10-20 | 2007-05-11 | Applied Research Systems | Derivados de 3-arilamino piridina. |
| PL2395004T3 (pl) | 2005-06-22 | 2016-08-31 | Plexxikon Inc | Pochodne pirolo[2,3-b]pirydyny jako inhibitory kinazy białkowej |
| DE602006021205D1 (de) | 2005-10-07 | 2011-05-19 | Exelixis Inc | Azetidine als mek-inhibitoren bei der behandlung proliferativer erkrankungen |
| GB0601962D0 (en) | 2006-01-31 | 2006-03-15 | Ucb Sa | Therapeutic agents |
| US7772233B2 (en) | 2006-04-19 | 2010-08-10 | Merck Serono, S.A. | Arylamino N-heteroaryl compounds as MEK inhibitors |
| GB0616214D0 (en) | 2006-08-15 | 2006-09-27 | Ucb Sa | Therapeutic Agents |
| JP2010500994A (ja) * | 2006-08-16 | 2010-01-14 | エグゼリクシス， インコーポレイテッド | Ｐｉ３ｋおよびｍｅｋモジュレーターを使用する方法 |
| MX2009001875A (es) | 2006-08-21 | 2009-03-02 | Genentech Inc | Compuestos de aza-benzotiofenilo y metodos de uso de los mismos. |
| EP2069354B1 (fr) | 2006-08-21 | 2011-11-02 | Genentech, Inc. | Composés aza-benzofuranyle et leurs procédés d'utilisation |
| RU2463038C2 (ru) | 2006-10-17 | 2012-10-10 | Нуво Рисерч Инк. | Диклофенаковый гель |
| WO2008055236A2 (fr) | 2006-10-31 | 2008-05-08 | Takeda Pharmaceutical Company Limited | Inhibiteurs de kinase mapk/erk |
| CL2007003444A1 (es) | 2006-11-30 | 2008-06-27 | Genentech Inc | Compuestos derivados de pirrolo[3,2-c]piridina; composicion farmaceutica; y uso en el tratamiento de un trastorno hiperproliferativo o una enfermedad inflamatoria. |
| US20090082328A1 (en) | 2007-05-11 | 2009-03-26 | Bayer Schering Pharma Aktiengesellschaft | Substituted phenylamino-benzene derivatives useful for treating hyper-proliferative disorders and diseases associated with mitogen extracellular kinase activity |
| WO2008148034A1 (fr) | 2007-05-25 | 2008-12-04 | Takeda Pharmaceutical Company Limited | Inhibiteurs de mapk/erk kinase |
| GB0714384D0 (en) | 2007-07-23 | 2007-09-05 | Ucb Pharma Sa | theraputic agents |
| NZ586575A (en) | 2007-12-21 | 2012-03-30 | Genentech Inc | Azaindolizines and methods of use |
| GB0801080D0 (en) | 2008-01-21 | 2008-02-27 | Ucb Pharma Sa | Therapeutic agents |
| GB0801081D0 (en) | 2008-01-21 | 2008-02-27 | Ucb Pharma Sa | Therapeutic agents |
| EP2240494B1 (fr) | 2008-01-21 | 2016-03-30 | UCB Biopharma SPRL | Dérivés de thiénopyridine utilisés comme inhibiteurs de mek |
| GB0811304D0 (en) | 2008-06-19 | 2008-07-30 | Ucb Pharma Sa | Therapeutic agents |
| EP2440204B1 (fr) | 2009-06-12 | 2013-12-18 | Bristol-Myers Squibb Company | Composés de nicotinamide utiles en tant que modulateurs de kinases |
| DE102010012594A1 (de) | 2010-03-23 | 2011-09-29 | Beiersdorf Ag | Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an einem oder mehreren Thiazolderivaten |
| WO2012040636A2 (fr) | 2010-09-24 | 2012-03-29 | The Broad Institute, Inc. | Composés et méthodes de traitement de maladies à médiation par des récepteurs activés par une protéase |
| PH12013500676A1 (en) | 2010-11-05 | 2013-05-06 | Hoffmann La Roche | Use of active pharmaceutical compounds for the treatment of central nervous system conditions |
| WO2012099968A1 (fr) | 2011-01-19 | 2012-07-26 | The Trustees Of The University Of Pennsylvania | Compositions et procédés de traitement de maladies associées à un cancer de la peau |
| GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
| WO2012171484A1 (fr) | 2011-06-17 | 2012-12-20 | 中国中化股份有限公司 | Composés de cyanoaniline substitués, leur préparation et leur utilisation |
| WO2014179785A1 (fr) | 2013-05-03 | 2014-11-06 | Inscent, Inc. | Répulsifs améliorés contre les abeilles domestiques et leurs utilisations |
| WO2014210538A1 (fr) | 2013-06-28 | 2014-12-31 | The Regents Of The University Of California | Traitement des déficits cognitifs associés au syndrome de noonan |
| US9572828B2 (en) | 2013-07-18 | 2017-02-21 | The Board Of Regents Of The University Of Texas System | Treatment for melanoma |
| CN105384754B (zh) * | 2014-09-02 | 2018-04-20 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途 |
| US20180256570A1 (en) | 2015-11-30 | 2018-09-13 | Ignyta, Inc. | Topical formulations |
| EP3301094A1 (fr) | 2016-09-30 | 2018-04-04 | Mutabilis | Nouveaux composés hétérocycliques et leur utilisation dans la prévention ou le traitement d'infections bactériennes |
| ES3030506T3 (en) | 2017-05-19 | 2025-06-30 | Nflection Therapeutics Inc | Pyrrolopyridine-aniline compounds for treatment of dermal disorders |
| EP3624795B1 (fr) | 2017-05-19 | 2022-04-20 | NFlection Therapeutics, Inc. | Composés hétéroaromatiques-aniline fusionnés pour le traitement de troubles dermiques |
| WO2019139970A1 (fr) | 2018-01-09 | 2019-07-18 | Duke University | Administration topique d'agents inhibiteurs de mek pour le traitement de troubles cutanés |
| WO2020101878A2 (fr) | 2018-10-29 | 2020-05-22 | The Johns Hopkins University | Traitement de rasopathie |
| JP7546297B2 (ja) | 2018-11-20 | 2024-09-06 | エヌフレクション セラピューティクス インコーポレイテッド | 皮膚障害の処置のためのチエニル－アニリン化合物 |
| MA55141A (fr) | 2018-11-20 | 2021-09-29 | Nflection Therapeutics Inc | Composés cyanoaryl-aniline pour le traitement d'affections de la peau |
| CA3120351A1 (fr) | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Composes aryl-aniline et heteroaryl-aniline pour le traitement de cancers de la peau |
| CA3120337A1 (fr) | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Composes naphthyridinone-aniline destines au traitement d'affections de la peau |
| WO2020106304A1 (fr) | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Formulations topiques |
| MA55148A (fr) | 2018-11-20 | 2021-09-29 | Nflection Therapeutics Inc | Composés d'aryl-aniline et d'hétéroaryl-aniline pour le traitement de marques de naissance |
| JP2023547040A (ja) | 2020-09-24 | 2023-11-09 | エヌフレクション セラピューティクス インコーポレイテッド | ピロロピリジン－アニリン化合物による、認知機能不全の処置方法 |
| WO2022159594A1 (fr) | 2021-01-21 | 2022-07-28 | Nflection Therapeutics, Inc. | Formes cristallines d'un composé de pyrrolopyridine-aniline |
| CA3205523A1 (fr) | 2021-01-21 | 2022-07-28 | Michael Houghton | Procedes de preparation de composes de pyrrolopyridine-aniline |
-
2019
- 2019-11-20 JP JP2021527910A patent/JP7546297B2/ja active Active
- 2019-11-20 CN CN202311548396.9A patent/CN117551073A/zh active Pending
- 2019-11-20 AU AU2019384645A patent/AU2019384645B2/en active Active
- 2019-11-20 CN CN201980089585.XA patent/CN113498340A/zh active Pending
- 2019-11-20 US US17/294,779 patent/US12466818B2/en active Active
- 2019-11-20 EP EP19887349.9A patent/EP3911313A4/fr active Pending
- 2019-11-20 WO PCT/US2019/000067 patent/WO2020106305A1/fr not_active Ceased
- 2019-11-20 MA MA054741A patent/MA54741A/fr unknown
- 2019-11-20 CA CA3120352A patent/CA3120352A1/fr active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3911313A4 (fr) | 2022-10-12 |
| US12466818B2 (en) | 2025-11-11 |
| CA3120352A1 (fr) | 2020-05-28 |
| AU2019384645A1 (en) | 2021-06-10 |
| EP3911313A1 (fr) | 2021-11-24 |
| CN113498340A (zh) | 2021-10-12 |
| AU2019384645B2 (en) | 2025-08-21 |
| CN117551073A (zh) | 2024-02-13 |
| WO2020106305A1 (fr) | 2020-05-28 |
| US20220204486A1 (en) | 2022-06-30 |
| JP7546297B2 (ja) | 2024-09-06 |
| JP2022510586A (ja) | 2022-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA49141A (fr) | Composés pyrrolopyridine-aniline destinés au traitement d'affections de la peau | |
| EP3911313A4 (fr) | Composés thiényl-aniline destinés au traitement d'affections de la peau | |
| MA54229A (fr) | Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp | |
| MA52575A (fr) | Pansement pour le traitement de la peau endommagée | |
| ECSP21093541A (es) | Compuestos para el tratamiento de enfermedades y trastornos asociados con braf | |
| EP3448389A4 (fr) | Composés de quinazoline et d'indole destinés au traitement de troubles médicaux | |
| IL271046A (en) | Compounds for treating huntington's disease | |
| IL286340A (en) | Topical formulations for treatment of peripheral neuropathies | |
| EP3704108A4 (fr) | Composés et compositions pour le traitement de troubles hématologiques | |
| EP3883567A4 (fr) | Composés naphthyridinone-aniline destinés au traitement d'affections de la peau | |
| MA55143A (fr) | Composés aryl-aniline et hétéroaryl-aniline pour le traitement de cancers de la peau | |
| EP3950686A4 (fr) | Dérivés d'amide n-hétéroaromatiques destinés au traitement du cancer | |
| EP3784260A4 (fr) | Compositions pour le traitement d'affections cutanées | |
| IL281809A (en) | Compositions and methods for treating disorders ameliorated by muscarinic receptor activation | |
| PL3405215T3 (pl) | Sposoby leczenia choroby danona i innych zaburzeń autofagii | |
| MA53664A (fr) | Composés destinés au traitement de certaines leucémies | |
| MA51672A (fr) | Composés destinés au traitement des troubles kinases-dépendants | |
| EP3790563A4 (fr) | Compositions permettant le traitement d'affections cutanées | |
| MA55141A (fr) | Composés cyanoaryl-aniline pour le traitement d'affections de la peau | |
| EP3672587A4 (fr) | Compositions pharmaceutiques destinées au traitement d'affections ophtalmiques | |
| EP3959213C0 (fr) | Inhibiteurs de jak à base de pyrimidine pour le traitement de maladies de la peau | |
| EP3773632A4 (fr) | Méthodes de traitement de glioblastomes exprimant l'egfrviii | |
| EP3593803A4 (fr) | Composés destinés au traitement de maladies causées par l'accumulation d'oxalate | |
| MA51738A (fr) | Composés pour le traitement de la douleur | |
| EP3927428A4 (fr) | Méthodes de traitement d'affections respiratoires |